AstraZeneca licenses novel triple reuptake inhibitors for depression
This article was originally published in Scrip
Executive Summary
AstraZeneca has licensed novel preclinical triple reuptake inhibitor (TRI) compounds that could have greater activity than existing treatments in neurological indications.